Phase I study of ceritinib in pediatric patients (Pts) with malignancies harboring a genetic alteration in ALK (ALK+): Safety, pharmacokinetic (PK), and efficacy results.-Reference-Cited by-同舟云学术

Phase I study of ceritinib in pediatric patients (Pts) with malignancies harboring a genetic alteration in ALK (ALK+): Safety, pharmacokinetic (PK), and efficacy results.

Published:2015-05-20 Issue:15_suppl Volume:33 Page:10005-10005
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Geoerger Birgit¹,Schulte Johannes²,Zwaan Christian M.³,Casanova Michela⁴,Fischer Matthias⁵,Moreno Lucas⁶,Trahair Toby⁷,Jimenez Irene⁸,Kang Hyoung Jin⁹,Pappo Alberto S.¹⁰,Schafer Eric¹¹,Weiss Brian D.¹²,Healy Mary Ellen¹³,Li Ke¹³,Lin Tiffany¹⁴,Boral Anthony¹⁵,Pearson Andrew DJ¹⁶

Affiliation:

1. Institut Gustave Roussy, Paris, France

2. University Hospital of Essen, Essen, Germany

3. Erasmus MC-Sophia Children's Hospital, Rotterdam, Netherlands

4. Fond. IRCCS Istituto Nazionale dei Tumori, Milan, Italy

5. University of Cologne, Cologne, Germany

6. Hospital Infantil Universitario Niño Jesús, Madrid, Spain

7. Sydney Children's Hospital, Randwick, Australia

8. Institut Curie, Paris, France

9. Department of Pediatric Hematology and Oncology, Seoul National University Children's Hospital, Seoul, South Korea

10. St. Jude Children's Research Hospital, Memphis, TN

11. Texas Children's Hospital, Houston, TX